Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.
In the Aria study, Triumeq showed statistical superiority over an atazanavir-containing regimen at 48 weeks in HIV-positive women.
Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.
On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.